Clinical epidemiology and impact of Haemophilus influenzae airway infections in adults with cystic fibrosis.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
27 Oct 2024
Historique:
received: 08 03 2024
accepted: 03 10 2024
medline: 28 10 2024
pubmed: 28 10 2024
entrez: 28 10 2024
Statut: epublish

Résumé

Haemophilus influenzae is prevalent within the airways of persons with cystic fibrosis (pwCF). H. influenzae is often associated with pulmonary exacerbations (PEx) in pediatric cohorts, but in adults, studies have yielded conflicting reports around the impact(s) on clinical outcomes such as lung function decline. Accordingly, we sought to discern the prevalence, natural history, and clinical impact of H. influenzae in adult pwCF. This single-centre retrospective cohort study reviewed all adult pwCF with H. influenzae sputum cultures between 2002 and 2016. From this cohort, persistently infected subjects (defined as: ≥2 samples with the same pulsotype and > 50% sputum culture-positive for H. influenzae in each year) were matched (1:2) to controls without H. influenzae. Demographic and clinical status (baseline health or during periods of PEx) were obtained at each visit that H. influenzae was cultured. Yearly biobank isolates were typed using pulsed-field gel electrophoresis (PFGE) to assess relatedness. Over the study period, 30% (n = 70/240) of pwCF were culture positive for H. influenzae, of which 38 (54%) were culture-positive on multiple occasions and 12 (17%) had persistent infection. One hundred and thirty-seven isolates underwent PFGE, with 94 unique pulsotypes identified. Two (1.5%) were serotype f with the rest non-typeable (98.5%). H. influenzae isolation was associated with an increased risk of PEx (RR = 1.61 [1.14-2.27], p = 0.006), however, this association was lost when we excluded those who irregularly produced sputum (i.e. only during a PEx). Annual lung function decline did not differ across cohorts. Isolation of H. influenzae was common amongst adult pwCF but often transient. H. influenzae infection was not associated with acute PEx or chronic lung function decline.

Sections du résumé

BACKGROUND BACKGROUND
Haemophilus influenzae is prevalent within the airways of persons with cystic fibrosis (pwCF). H. influenzae is often associated with pulmonary exacerbations (PEx) in pediatric cohorts, but in adults, studies have yielded conflicting reports around the impact(s) on clinical outcomes such as lung function decline. Accordingly, we sought to discern the prevalence, natural history, and clinical impact of H. influenzae in adult pwCF.
METHODS METHODS
This single-centre retrospective cohort study reviewed all adult pwCF with H. influenzae sputum cultures between 2002 and 2016. From this cohort, persistently infected subjects (defined as: ≥2 samples with the same pulsotype and > 50% sputum culture-positive for H. influenzae in each year) were matched (1:2) to controls without H. influenzae. Demographic and clinical status (baseline health or during periods of PEx) were obtained at each visit that H. influenzae was cultured. Yearly biobank isolates were typed using pulsed-field gel electrophoresis (PFGE) to assess relatedness.
RESULTS RESULTS
Over the study period, 30% (n = 70/240) of pwCF were culture positive for H. influenzae, of which 38 (54%) were culture-positive on multiple occasions and 12 (17%) had persistent infection. One hundred and thirty-seven isolates underwent PFGE, with 94 unique pulsotypes identified. Two (1.5%) were serotype f with the rest non-typeable (98.5%). H. influenzae isolation was associated with an increased risk of PEx (RR = 1.61 [1.14-2.27], p = 0.006), however, this association was lost when we excluded those who irregularly produced sputum (i.e. only during a PEx). Annual lung function decline did not differ across cohorts.
CONCLUSIONS CONCLUSIONS
Isolation of H. influenzae was common amongst adult pwCF but often transient. H. influenzae infection was not associated with acute PEx or chronic lung function decline.

Identifiants

pubmed: 39465381
doi: 10.1186/s12879-024-10050-7
pii: 10.1186/s12879-024-10050-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1209

Informations de copyright

© 2024. The Author(s).

Références

Coburn B, Wang PW, Diaz Caballero J, Clark ST, Brahma V, Donaldson S, et al. Lung microbiota across age and disease stage in cystic fibrosis. Sci Rep. 2015;5:10241.
doi: 10.1038/srep10241 pubmed: 25974282 pmcid: 4431465
Zemanick ET, Wagner BD, Robertson CE, Ahrens RC, Chmiel JF, Clancy JP et al. Airway Microbiota across age and disease spectrum in cystic fibrosis. European Respiratory Journal. 2017 Nov 1; 50(5).
Zhao J, Schloss PD, Kalikin LM, Carmody LA, Foster BK, Petrosino JF, et al. Decade-long bacterial community dynamics in cystic fibrosis airways. Proc Natl Acad Sci U S A. 2012;109(15):5809–14.
doi: 10.1073/pnas.1120577109 pubmed: 22451929 pmcid: 3326496
Cystic Fibrosis Foundation Patient Registry. 2019 Annual Data Report [Internet]. 2019 [cited 2024 Feb 8]. https://www.cff.org/sites/default/files/2021-10/2019-Patient-Registry-Annual-Data-Report.pdf
LiPuma JJ. The changing Microbial Epidemiology in cystic fibrosis. Clin Microbiol Rev. 2010;23(2):299–323.
doi: 10.1128/CMR.00068-09 pubmed: 20375354 pmcid: 2863368
Román F, Cantón R, Pérez-Vázquez M, Baquero F, Campos J. Dynamics of Long-Term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in Hypermutable Strains. J Clin Microbiol. 2004;42(4):1450–9.
doi: 10.1128/JCM.42.4.1450-1459.2004 pubmed: 15070988 pmcid: 387613
Rayner RJ, Hiller EJ, Ispahani P, Baker M. Haemophilus infection in cystic fibrosis. Arch Dis Child. 1990;65(3):255–8.
doi: 10.1136/adc.65.3.255 pubmed: 2185699 pmcid: 1792300
UK Cystic Fibrosis Trust Antibiotic Working Group. Antibiotic treatment for cystic fibrosis – 3rd edition [Internet]. 2009. https://www.cysticfibrosis.org.uk/sites/default/files/2020-11/Anitbiotic%20Treatment.pdf
Spilker T, Vandamme P, LiPuma JJ. A multilocus sequence typing scheme implies population structure and reveals several putative novel achromobacter species. J Clin Microbiol. 2012;50(9):3010–5.
doi: 10.1128/JCM.00814-12 pubmed: 22785192 pmcid: 3421806
Parkins MD, Glezerson BA, Sibley CD, Sibley KA, Duong J, Purighalla S, et al. Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain. J Clin Microbiol. 2014;52(4):1127–35.
doi: 10.1128/JCM.03218-13 pubmed: 24452167 pmcid: 3993468
Izydorczyk C, Waddell BJ, Weyant RB, Surette MG, Somayaji R, Rabin HR, et al. The natural history and genetic diversity of Haemophilus influenzae infecting the airways of adults with cystic fibrosis. Sci Rep. 2022;12(1):15765.
doi: 10.1038/s41598-022-19240-2 pubmed: 36131075 pmcid: 9492733
Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med. 1994;331(10):637–42.
doi: 10.1056/NEJM199409083311003 pubmed: 7503821
Lam JC, Somayaji R, Surette MG, Rabin HR, Parkins MD. Reduction in Pseudomonas aeruginosa Sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response. BMC Infect Dis. 2015;15(1):145.
doi: 10.1186/s12879-015-0856-5 pubmed: 25887462 pmcid: 4392784
Performance Standards for Antimicrobial Susceptibility Testing. In. CLSI. 27th ed. Wayne, PA: Clinical and Laboratory Standards Institute; 2017. CLSI Supplement M100.
Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol. 1995;33(9):2233–9.
doi: 10.1128/jcm.33.9.2233-2239.1995 pubmed: 7494007 pmcid: 228385
Davis GS, Sandstedt SA, Patel M, Marrs CF, Gilsdorf JR. Use of bexB to detect the Capsule Locus in Haemophilus influenzae. J Clin Microbiol. 2011;49(7):2594–601.
doi: 10.1128/JCM.02509-10 pubmed: 21525217 pmcid: 3147886
Potts CC, Topaz N, Rodriguez-Rivera LD, Hu F, Chang HY, Whaley MJ, et al. Genomic characterization of Haemophilus influenzae: a focus on the capsule locus. BMC Genomics. 2019;20(1):733.
doi: 10.1186/s12864-019-6145-8 pubmed: 31606037 pmcid: 6790013
Watts SC, Judd LM, Carzino R, Ranganathan S, Holt KE. Genomic diversity and Antimicrobial Resistance of Haemophilus colonizing the airways of Young children with cystic fibrosis. mSystems. 2021;6(4):e00178-21.
Cardines R, Giufrè M, Pompilio A, Fiscarelli E, Ricciotti G, Bonaventura GD, et al. Haemophilus influenzae in children with cystic fibrosis: Antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation. Int J Med Microbiol. 2012;302(1):45–52.
doi: 10.1016/j.ijmm.2011.08.003 pubmed: 22001303
Möller LVM, Regelink AG, Grasselier H, Dankert-Roelse JE, Dankert J, van Alphen L. Multiple Haemophilus influenzae strains and strain variants coexist in the respiratory tract of patients with cystic fibrosis. J Infect Dis. 1995;172(5):1388–92.
doi: 10.1093/infdis/172.5.1388 pubmed: 7594685
Adam HJ, Richardson SE, Jamieson FB, Rawte P, Low DE, Fisman DN. Changing epidemiology of invasive Haemophilus influenzae in Ontario, Canada: evidence for herd effects and strain replacement due to Hib vaccination. Vaccine. 2010;28(24):4073–8.
doi: 10.1016/j.vaccine.2010.03.075 pubmed: 20398617
McTaggart LR, Cronin K, Seo CY, Wilson S, Patel SN, Kus JV. Increased incidence of Invasive Haemophilus influenzae Disease Driven by Non-type B isolates in Ontario, Canada, 2014 to 2018. Microbiol Spectr. 2021;9(2):e00803–21.
doi: 10.1128/Spectrum.00803-21 pubmed: 34612671 pmcid: 8510165
Digoy GP, Dunn JD, Stoner JA, Christie A, Jones DT. Bacteriology of the paranasal sinuses in pediatric cystic fibrosis patients. Int J Pediatr Otorhinolaryngol. 2012;76(7):934–8.
doi: 10.1016/j.ijporl.2012.02.043 pubmed: 22513080
Muhlebach MS, Miller MB, Moore C, Wedd JP, Drake AF, Leigh MW. Are lower airway or throat cultures predictive of sinus bacteriology in cystic fibrosis? Pediatr Pulmonol. 2006;41(5):445–51.
doi: 10.1002/ppul.20396 pubmed: 16547960
Woo TE, Lim R, Heirali AA, Acosta N, Rabin HR, Mody CH, et al. A longitudinal characterization of the Non-cystic Fibrosis Bronchiectasis airway microbiome. Sci Rep. 2019;9(1):6871.
doi: 10.1038/s41598-019-42862-y pubmed: 31053725 pmcid: 6499777
Rogers GB, van der Gast CJ, Serisier DJ. Predominant pathogen competition and core microbiota divergence in chronic airway infection. ISME J. 2015;9(1):217–25.
doi: 10.1038/ismej.2014.124 pubmed: 25036925
Crull MR, Somayaji R, Ramos KJ, Caldwell E, Mayer-Hamblett N, Aitken ML, et al. Changing Rates of Chronic Pseudomonas aeruginosa infections in cystic fibrosis: a Population-based Cohort Study. Clin Infect Dis. 2018;67(7):1089–95.
doi: 10.1093/cid/ciy215 pubmed: 29534149 pmcid: 6137120
Hewer SCL, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews. 2017;(4).
Sosinski LM, Neugebauer HCM, Ghuneim KA, Guzior LAJ, Castillo-Bahena DV. A restructuring of microbiome niche space is associated with Elexacaftor-Tezacaftor-Ivacaftor therapy in the cystic fibrosis lung. J Cyst Fibros off J Eur Cyst Fibros Soc. 2022;21(6):996–1005.
doi: 10.1016/j.jcf.2021.11.003
Gessner B, Njanpop-Lafourcade BM, Herbert M. Haemophilus influenzae- Infectious Disease and Antimicrobial Agents [Internet]. [cited 2024 Feb 8]. http://antimicrobe.org/b67.asp
Finland M, Garner C, Wilcox C, Sabath LD. Susceptibility of Pneumococci and Haemophilus influenzae to Antibacterial agents. Antimicrob Agents Chemother. 1976;9(2):274–87.
doi: 10.1128/AAC.9.2.274 pubmed: 5052 pmcid: 429515

Auteurs

R Benson Weyant (RB)

Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada.

Barbara J Waddell (BJ)

Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada.

Nicole Acosta (N)

Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada.

Conrad Izydorczyk (C)

Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada.

John M Conly (JM)

Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada.
Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada.
Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, AB, Canada.

Deirdre L Church (DL)

Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada.
Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada.
Department of Pathology and Laboratory Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, AB, Canada.

Michael G Surette (MG)

Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada.

Harvey R Rabin (HR)

Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada.
Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada.

Christina S Thornton (CS)

Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada.
Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada.

Michael D Parkins (MD)

Department of Medicine, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada. mdparkin@ucalgary.ca.
Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, Canada. mdparkin@ucalgary.ca.
Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary and Alberta Health Services, Calgary, Canada. mdparkin@ucalgary.ca.
Departments of Medicine and Microbiology, Immunology and Infectious Diseases Southern Alberta Adult Cystic Fibrosis Clinic, Division of Infectious Diseases, Alberta Health Services, Calgary, Canada. mdparkin@ucalgary.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH